chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Alanine aminotransferase normal, Albumin globulin ratio normal, Anion gap normal, Antinuclear antibody negative, Aspartate aminotransferase normal
Clinical narrative: On April 5th, patient received the J&J covid vaccine from her PCP and admits to perioral itching approximately 10-15 minutes after receiving the vaccine. She believed her symptoms were secondary to eczema and went home after getting the vaccine. When she arrived home, she had developed both lip and tongue swelling. She called her primary care doctor and was recommended to take Benadryl 25mg and head to the ER. She felt very tired and instead of going to the ER she fell asleep. The next morning, she continued to experience perioral itching, lip swelling, and tongue swelling and went to a local emergency room where she was treated with IM epinephrine and discharged on pepsid/prednisone/benadryl. She noted improvement in her symptoms at this point and continued on Prednisone 40mg. However, one day later, she noticed the lip swelling and tongue swelling return and developed shortness of breath. She returned to the ER and was given IM epinephrine which helped her symptoms significantly. She was continued on Pepcid/Prednisone/Benadryl and discharged from the ER. Ultimately this continued for the last two weeks and last Friday, she was hospitalized at from April 16 to April 19. She was given racemic epinephrine and felt that was the most helpful in terms of alleviating her shortness of breath. While at hospital, she was started on Singulair, Zyrtec, Pepcid, and Benadryl.  She was evaluated by an Allergist on 4/19/21 and underwent an autoimmune workup (ANA, RF, ESR, CRP) and angioedema workup (C3, C4, C1INH, tryptase) which was reported as being unremarkable. She was also given a shot of Xolair however she has not noticed any improvement in her symptoms.  She came to the hospital yesterday due to continued symptoms and return of shortness of breath. She additionally began experiencing headaches and double vision consistent with her migraines but definitely worse than her past headaches. She was admitted to the the ICU and evaluated by ENT with laryngoscopy (unremarkable). She was started on Methylprednisolone with racemic epinephrine. She has been started on treatment with Firazyr (icatibant) 30mg which has helped with tongue swelling.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Basophil count normal, Basophil percentage, Blood albumin normal, Blood alkaline phosphatase normal, Blood bilirubin normal
Clinical narrative: On April 5th, patient received the J&J covid vaccine from her PCP and admits to perioral itching approximately 10-15 minutes after receiving the vaccine. She believed her symptoms were secondary to eczema and went home after getting the vaccine. When she arrived home, she had developed both lip and tongue swelling. She called her primary care doctor and was recommended to take Benadryl 25mg and head to the ER. She felt very tired and instead of going to the ER she fell asleep. The next morning, she continued to experience perioral itching, lip swelling, and tongue swelling and went to a local emergency room where she was treated with IM epinephrine and discharged on pepsid/prednisone/benadryl. She noted improvement in her symptoms at this point and continued on Prednisone 40mg. However, one day later, she noticed the lip swelling and tongue swelling return and developed shortness of breath. She returned to the ER and was given IM epinephrine which helped her symptoms significantly. She was continued on Pepcid/Prednisone/Benadryl and discharged from the ER. Ultimately this continued for the last two weeks and last Friday, she was hospitalized at from April 16 to April 19. She was given racemic epinephrine and felt that was the most helpful in terms of alleviating her shortness of breath. While at hospital, she was started on Singulair, Zyrtec, Pepcid, and Benadryl.  She was evaluated by an Allergist on 4/19/21 and underwent an autoimmune workup (ANA, RF, ESR, CRP) and angioedema workup (C3, C4, C1INH, tryptase) which was reported as being unremarkable. She was also given a shot of Xolair however she has not noticed any improvement in her symptoms.  She came to the hospital yesterday due to continued symptoms and return of shortness of breath. She additionally began experiencing headaches and double vision consistent with her migraines but definitely worse than her past headaches. She was admitted to the the ICU and evaluated by ENT with laryngoscopy (unremarkable). She was started on Methylprednisolone with racemic epinephrine. She has been started on treatment with Firazyr (icatibant) 30mg which has helped with tongue swelling.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blood calcium normal, Blood chloride increased, Blood creatinine normal, Blood glucose normal, Blood potassium normal
Clinical narrative: On April 5th, patient received the J&J covid vaccine from her PCP and admits to perioral itching approximately 10-15 minutes after receiving the vaccine. She believed her symptoms were secondary to eczema and went home after getting the vaccine. When she arrived home, she had developed both lip and tongue swelling. She called her primary care doctor and was recommended to take Benadryl 25mg and head to the ER. She felt very tired and instead of going to the ER she fell asleep. The next morning, she continued to experience perioral itching, lip swelling, and tongue swelling and went to a local emergency room where she was treated with IM epinephrine and discharged on pepsid/prednisone/benadryl. She noted improvement in her symptoms at this point and continued on Prednisone 40mg. However, one day later, she noticed the lip swelling and tongue swelling return and developed shortness of breath. She returned to the ER and was given IM epinephrine which helped her symptoms significantly. She was continued on Pepcid/Prednisone/Benadryl and discharged from the ER. Ultimately this continued for the last two weeks and last Friday, she was hospitalized at from April 16 to April 19. She was given racemic epinephrine and felt that was the most helpful in terms of alleviating her shortness of breath. While at hospital, she was started on Singulair, Zyrtec, Pepcid, and Benadryl.  She was evaluated by an Allergist on 4/19/21 and underwent an autoimmune workup (ANA, RF, ESR, CRP) and angioedema workup (C3, C4, C1INH, tryptase) which was reported as being unremarkable. She was also given a shot of Xolair however she has not noticed any improvement in her symptoms.  She came to the hospital yesterday due to continued symptoms and return of shortness of breath. She additionally began experiencing headaches and double vision consistent with her migraines but definitely worse than her past headaches. She was admitted to the the ICU and evaluated by ENT with laryngoscopy (unremarkable). She was started on Methylprednisolone with racemic epinephrine. She has been started on treatment with Firazyr (icatibant) 30mg which has helped with tongue swelling.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blood sodium normal, Blood thyroid stimulating hormone decreased, Blood urea normal, C-reactive protein normal, C1 esterase inhibitor test normal
Clinical narrative: On April 5th, patient received the J&J covid vaccine from her PCP and admits to perioral itching approximately 10-15 minutes after receiving the vaccine. She believed her symptoms were secondary to eczema and went home after getting the vaccine. When she arrived home, she had developed both lip and tongue swelling. She called her primary care doctor and was recommended to take Benadryl 25mg and head to the ER. She felt very tired and instead of going to the ER she fell asleep. The next morning, she continued to experience perioral itching, lip swelling, and tongue swelling and went to a local emergency room where she was treated with IM epinephrine and discharged on pepsid/prednisone/benadryl. She noted improvement in her symptoms at this point and continued on Prednisone 40mg. However, one day later, she noticed the lip swelling and tongue swelling return and developed shortness of breath. She returned to the ER and was given IM epinephrine which helped her symptoms significantly. She was continued on Pepcid/Prednisone/Benadryl and discharged from the ER. Ultimately this continued for the last two weeks and last Friday, she was hospitalized at from April 16 to April 19. She was given racemic epinephrine and felt that was the most helpful in terms of alleviating her shortness of breath. While at hospital, she was started on Singulair, Zyrtec, Pepcid, and Benadryl.  She was evaluated by an Allergist on 4/19/21 and underwent an autoimmune workup (ANA, RF, ESR, CRP) and angioedema workup (C3, C4, C1INH, tryptase) which was reported as being unremarkable. She was also given a shot of Xolair however she has not noticed any improvement in her symptoms.  She came to the hospital yesterday due to continued symptoms and return of shortness of breath. She additionally began experiencing headaches and double vision consistent with her migraines but definitely worse than her past headaches. She was admitted to the the ICU and evaluated by ENT with laryngoscopy (unremarkable). She was started on Methylprednisolone with racemic epinephrine. She has been started on treatment with Firazyr (icatibant) 30mg which has helped with tongue swelling.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Carbon dioxide normal, Complement factor C3, Complement factor C4, Eosinophil count decreased, Eosinophil percentage decreased
Clinical narrative: On April 5th, patient received the J&J covid vaccine from her PCP and admits to perioral itching approximately 10-15 minutes after receiving the vaccine. She believed her symptoms were secondary to eczema and went home after getting the vaccine. When she arrived home, she had developed both lip and tongue swelling. She called her primary care doctor and was recommended to take Benadryl 25mg and head to the ER. She felt very tired and instead of going to the ER she fell asleep. The next morning, she continued to experience perioral itching, lip swelling, and tongue swelling and went to a local emergency room where she was treated with IM epinephrine and discharged on pepsid/prednisone/benadryl. She noted improvement in her symptoms at this point and continued on Prednisone 40mg. However, one day later, she noticed the lip swelling and tongue swelling return and developed shortness of breath. She returned to the ER and was given IM epinephrine which helped her symptoms significantly. She was continued on Pepcid/Prednisone/Benadryl and discharged from the ER. Ultimately this continued for the last two weeks and last Friday, she was hospitalized at from April 16 to April 19. She was given racemic epinephrine and felt that was the most helpful in terms of alleviating her shortness of breath. While at hospital, she was started on Singulair, Zyrtec, Pepcid, and Benadryl.  She was evaluated by an Allergist on 4/19/21 and underwent an autoimmune workup (ANA, RF, ESR, CRP) and angioedema workup (C3, C4, C1INH, tryptase) which was reported as being unremarkable. She was also given a shot of Xolair however she has not noticed any improvement in her symptoms.  She came to the hospital yesterday due to continued symptoms and return of shortness of breath. She additionally began experiencing headaches and double vision consistent with her migraines but definitely worse than her past headaches. She was admitted to the the ICU and evaluated by ENT with laryngoscopy (unremarkable). She was started on Methylprednisolone with racemic epinephrine. She has been started on treatment with Firazyr (icatibant) 30mg which has helped with tongue swelling.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Globulin, Glomerular filtration rate normal, Granulocyte percentage, Haematocrit normal, Haemoglobin normal
Clinical narrative: On April 5th, patient received the J&J covid vaccine from her PCP and admits to perioral itching approximately 10-15 minutes after receiving the vaccine. She believed her symptoms were secondary to eczema and went home after getting the vaccine. When she arrived home, she had developed both lip and tongue swelling. She called her primary care doctor and was recommended to take Benadryl 25mg and head to the ER. She felt very tired and instead of going to the ER she fell asleep. The next morning, she continued to experience perioral itching, lip swelling, and tongue swelling and went to a local emergency room where she was treated with IM epinephrine and discharged on pepsid/prednisone/benadryl. She noted improvement in her symptoms at this point and continued on Prednisone 40mg. However, one day later, she noticed the lip swelling and tongue swelling return and developed shortness of breath. She returned to the ER and was given IM epinephrine which helped her symptoms significantly. She was continued on Pepcid/Prednisone/Benadryl and discharged from the ER. Ultimately this continued for the last two weeks and last Friday, she was hospitalized at from April 16 to April 19. She was given racemic epinephrine and felt that was the most helpful in terms of alleviating her shortness of breath. While at hospital, she was started on Singulair, Zyrtec, Pepcid, and Benadryl.  She was evaluated by an Allergist on 4/19/21 and underwent an autoimmune workup (ANA, RF, ESR, CRP) and angioedema workup (C3, C4, C1INH, tryptase) which was reported as being unremarkable. She was also given a shot of Xolair however she has not noticed any improvement in her symptoms.  She came to the hospital yesterday due to continued symptoms and return of shortness of breath. She additionally began experiencing headaches and double vision consistent with her migraines but definitely worse than her past headaches. She was admitted to the the ICU and evaluated by ENT with laryngoscopy (unremarkable). She was started on Methylprednisolone with racemic epinephrine. She has been started on treatment with Firazyr (icatibant) 30mg which has helped with tongue swelling.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Human chorionic gonadotropin negative, Immature granulocyte count, Inflammation, Lip swelling, Lymphocyte count normal
Clinical narrative: On April 5th, patient received the J&J covid vaccine from her PCP and admits to perioral itching approximately 10-15 minutes after receiving the vaccine. She believed her symptoms were secondary to eczema and went home after getting the vaccine. When she arrived home, she had developed both lip and tongue swelling. She called her primary care doctor and was recommended to take Benadryl 25mg and head to the ER. She felt very tired and instead of going to the ER she fell asleep. The next morning, she continued to experience perioral itching, lip swelling, and tongue swelling and went to a local emergency room where she was treated with IM epinephrine and discharged on pepsid/prednisone/benadryl. She noted improvement in her symptoms at this point and continued on Prednisone 40mg. However, one day later, she noticed the lip swelling and tongue swelling return and developed shortness of breath. She returned to the ER and was given IM epinephrine which helped her symptoms significantly. She was continued on Pepcid/Prednisone/Benadryl and discharged from the ER. Ultimately this continued for the last two weeks and last Friday, she was hospitalized at from April 16 to April 19. She was given racemic epinephrine and felt that was the most helpful in terms of alleviating her shortness of breath. While at hospital, she was started on Singulair, Zyrtec, Pepcid, and Benadryl.  She was evaluated by an Allergist on 4/19/21 and underwent an autoimmune workup (ANA, RF, ESR, CRP) and angioedema workup (C3, C4, C1INH, tryptase) which was reported as being unremarkable. She was also given a shot of Xolair however she has not noticed any improvement in her symptoms.  She came to the hospital yesterday due to continued symptoms and return of shortness of breath. She additionally began experiencing headaches and double vision consistent with her migraines but definitely worse than her past headaches. She was admitted to the the ICU and evaluated by ENT with laryngoscopy (unremarkable). She was started on Methylprednisolone with racemic epinephrine. She has been started on treatment with Firazyr (icatibant) 30mg which has helped with tongue swelling.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Lymphocyte percentage decreased, Mean cell haemoglobin concentration normal, Mean cell haemoglobin normal, Mean cell volume normal, Mean platelet volume increased
Clinical narrative: On April 5th, patient received the J&J covid vaccine from her PCP and admits to perioral itching approximately 10-15 minutes after receiving the vaccine. She believed her symptoms were secondary to eczema and went home after getting the vaccine. When she arrived home, she had developed both lip and tongue swelling. She called her primary care doctor and was recommended to take Benadryl 25mg and head to the ER. She felt very tired and instead of going to the ER she fell asleep. The next morning, she continued to experience perioral itching, lip swelling, and tongue swelling and went to a local emergency room where she was treated with IM epinephrine and discharged on pepsid/prednisone/benadryl. She noted improvement in her symptoms at this point and continued on Prednisone 40mg. However, one day later, she noticed the lip swelling and tongue swelling return and developed shortness of breath. She returned to the ER and was given IM epinephrine which helped her symptoms significantly. She was continued on Pepcid/Prednisone/Benadryl and discharged from the ER. Ultimately this continued for the last two weeks and last Friday, she was hospitalized at from April 16 to April 19. She was given racemic epinephrine and felt that was the most helpful in terms of alleviating her shortness of breath. While at hospital, she was started on Singulair, Zyrtec, Pepcid, and Benadryl.  She was evaluated by an Allergist on 4/19/21 and underwent an autoimmune workup (ANA, RF, ESR, CRP) and angioedema workup (C3, C4, C1INH, tryptase) which was reported as being unremarkable. She was also given a shot of Xolair however she has not noticed any improvement in her symptoms.  She came to the hospital yesterday due to continued symptoms and return of shortness of breath. She additionally began experiencing headaches and double vision consistent with her migraines but definitely worse than her past headaches. She was admitted to the the ICU and evaluated by ENT with laryngoscopy (unremarkable). She was started on Methylprednisolone with racemic epinephrine. She has been started on treatment with Firazyr (icatibant) 30mg which has helped with tongue swelling.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Monocyte count normal, Monocyte percentage, Neutrophil count normal, Neutrophil percentage increased, Nucleated red cells
Clinical narrative: On April 5th, patient received the J&J covid vaccine from her PCP and admits to perioral itching approximately 10-15 minutes after receiving the vaccine. She believed her symptoms were secondary to eczema and went home after getting the vaccine. When she arrived home, she had developed both lip and tongue swelling. She called her primary care doctor and was recommended to take Benadryl 25mg and head to the ER. She felt very tired and instead of going to the ER she fell asleep. The next morning, she continued to experience perioral itching, lip swelling, and tongue swelling and went to a local emergency room where she was treated with IM epinephrine and discharged on pepsid/prednisone/benadryl. She noted improvement in her symptoms at this point and continued on Prednisone 40mg. However, one day later, she noticed the lip swelling and tongue swelling return and developed shortness of breath. She returned to the ER and was given IM epinephrine which helped her symptoms significantly. She was continued on Pepcid/Prednisone/Benadryl and discharged from the ER. Ultimately this continued for the last two weeks and last Friday, she was hospitalized at from April 16 to April 19. She was given racemic epinephrine and felt that was the most helpful in terms of alleviating her shortness of breath. While at hospital, she was started on Singulair, Zyrtec, Pepcid, and Benadryl.  She was evaluated by an Allergist on 4/19/21 and underwent an autoimmune workup (ANA, RF, ESR, CRP) and angioedema workup (C3, C4, C1INH, tryptase) which was reported as being unremarkable. She was also given a shot of Xolair however she has not noticed any improvement in her symptoms.  She came to the hospital yesterday due to continued symptoms and return of shortness of breath. She additionally began experiencing headaches and double vision consistent with her migraines but definitely worse than her past headaches. She was admitted to the the ICU and evaluated by ENT with laryngoscopy (unremarkable). She was started on Methylprednisolone with racemic epinephrine. She has been started on treatment with Firazyr (icatibant) 30mg which has helped with tongue swelling.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Platelet count normal, Protein total normal, Pruritus, Red blood cell count normal, Red blood cell nucleated morphology
Clinical narrative: On April 5th, patient received the J&J covid vaccine from her PCP and admits to perioral itching approximately 10-15 minutes after receiving the vaccine. She believed her symptoms were secondary to eczema and went home after getting the vaccine. When she arrived home, she had developed both lip and tongue swelling. She called her primary care doctor and was recommended to take Benadryl 25mg and head to the ER. She felt very tired and instead of going to the ER she fell asleep. The next morning, she continued to experience perioral itching, lip swelling, and tongue swelling and went to a local emergency room where she was treated with IM epinephrine and discharged on pepsid/prednisone/benadryl. She noted improvement in her symptoms at this point and continued on Prednisone 40mg. However, one day later, she noticed the lip swelling and tongue swelling return and developed shortness of breath. She returned to the ER and was given IM epinephrine which helped her symptoms significantly. She was continued on Pepcid/Prednisone/Benadryl and discharged from the ER. Ultimately this continued for the last two weeks and last Friday, she was hospitalized at from April 16 to April 19. She was given racemic epinephrine and felt that was the most helpful in terms of alleviating her shortness of breath. While at hospital, she was started on Singulair, Zyrtec, Pepcid, and Benadryl.  She was evaluated by an Allergist on 4/19/21 and underwent an autoimmune workup (ANA, RF, ESR, CRP) and angioedema workup (C3, C4, C1INH, tryptase) which was reported as being unremarkable. She was also given a shot of Xolair however she has not noticed any improvement in her symptoms.  She came to the hospital yesterday due to continued symptoms and return of shortness of breath. She additionally began experiencing headaches and double vision consistent with her migraines but definitely worse than her past headaches. She was admitted to the the ICU and evaluated by ENT with laryngoscopy (unremarkable). She was started on Methylprednisolone with racemic epinephrine. She has been started on treatment with Firazyr (icatibant) 30mg which has helped with tongue swelling.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Red blood cell sedimentation rate normal, Red cell distribution width normal, Reflex test normal, Rheumatoid factor negative, Tongue pruritus
Clinical narrative: On April 5th, patient received the J&J covid vaccine from her PCP and admits to perioral itching approximately 10-15 minutes after receiving the vaccine. She believed her symptoms were secondary to eczema and went home after getting the vaccine. When she arrived home, she had developed both lip and tongue swelling. She called her primary care doctor and was recommended to take Benadryl 25mg and head to the ER. She felt very tired and instead of going to the ER she fell asleep. The next morning, she continued to experience perioral itching, lip swelling, and tongue swelling and went to a local emergency room where she was treated with IM epinephrine and discharged on pepsid/prednisone/benadryl. She noted improvement in her symptoms at this point and continued on Prednisone 40mg. However, one day later, she noticed the lip swelling and tongue swelling return and developed shortness of breath. She returned to the ER and was given IM epinephrine which helped her symptoms significantly. She was continued on Pepcid/Prednisone/Benadryl and discharged from the ER. Ultimately this continued for the last two weeks and last Friday, she was hospitalized at from April 16 to April 19. She was given racemic epinephrine and felt that was the most helpful in terms of alleviating her shortness of breath. While at hospital, she was started on Singulair, Zyrtec, Pepcid, and Benadryl.  She was evaluated by an Allergist on 4/19/21 and underwent an autoimmune workup (ANA, RF, ESR, CRP) and angioedema workup (C3, C4, C1INH, tryptase) which was reported as being unremarkable. She was also given a shot of Xolair however she has not noticed any improvement in her symptoms.  She came to the hospital yesterday due to continued symptoms and return of shortness of breath. She additionally began experiencing headaches and double vision consistent with her migraines but definitely worse than her past headaches. She was admitted to the the ICU and evaluated by ENT with laryngoscopy (unremarkable). She was started on Methylprednisolone with racemic epinephrine. She has been started on treatment with Firazyr (icatibant) 30mg which has helped with tongue swelling.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Tryptase, White blood cell count normal
Clinical narrative: On April 5th, patient received the J&J covid vaccine from her PCP and admits to perioral itching approximately 10-15 minutes after receiving the vaccine. She believed her symptoms were secondary to eczema and went home after getting the vaccine. When she arrived home, she had developed both lip and tongue swelling. She called her primary care doctor and was recommended to take Benadryl 25mg and head to the ER. She felt very tired and instead of going to the ER she fell asleep. The next morning, she continued to experience perioral itching, lip swelling, and tongue swelling and went to a local emergency room where she was treated with IM epinephrine and discharged on pepsid/prednisone/benadryl. She noted improvement in her symptoms at this point and continued on Prednisone 40mg. However, one day later, she noticed the lip swelling and tongue swelling return and developed shortness of breath. She returned to the ER and was given IM epinephrine which helped her symptoms significantly. She was continued on Pepcid/Prednisone/Benadryl and discharged from the ER. Ultimately this continued for the last two weeks and last Friday, she was hospitalized at from April 16 to April 19. She was given racemic epinephrine and felt that was the most helpful in terms of alleviating her shortness of breath. While at hospital, she was started on Singulair, Zyrtec, Pepcid, and Benadryl.  She was evaluated by an Allergist on 4/19/21 and underwent an autoimmune workup (ANA, RF, ESR, CRP) and angioedema workup (C3, C4, C1INH, tryptase) which was reported as being unremarkable. She was also given a shot of Xolair however she has not noticed any improvement in her symptoms.  She came to the hospital yesterday due to continued symptoms and return of shortness of breath. She additionally began experiencing headaches and double vision consistent with her migraines but definitely worse than her past headaches. She was admitted to the the ICU and evaluated by ENT with laryngoscopy (unremarkable). She was started on Methylprednisolone with racemic epinephrine. She has been started on treatment with Firazyr (icatibant) 30mg which has helped with tongue swelling.
Age: 46.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Chest pain, Dyspnoea, Headache, Hyperhidrosis, Injection site vesicles
Clinical narrative: BLISTERS ON RIGHT ARM BETWEEN ELBOW AND SHOULDER; SHORTNESS OF BREATH; BLURRED VISION; ITCHING ALL OVER ESPECIALLY IN RIGHT ARM; FEVER OF 101 F; TIREDNESS; SCAR ON ARM THAT WAS 4 INCHES LONG AND 2 INCHES WIDE; This spontaneous report received from a patient concerned a 46 year old male. The patient's weight was 225 pounds, and height was 66 inches. The patient's past medical history included umbilical hernia, and covid-19, and concurrent conditions included high cholesterol, non-smoker, and social alcohol drinker, and other pre-existing medical conditions included the patient had no known allergies. The patient had no history of drug abuse or illicit drug use. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 206A21A, expiry: UNKNOWN) dose was not reported, administered on 12-APR-2021 for prophylactic vaccination. Concomitant medications included atorvastatin calcium for high cholesterol. On APR-2021, treatment medications included: diphenhydramine hydrochloride, oxygen, and paracetamol. Also given unspecified cream for right arm. He wanted help with the scar on arm that was 4 inches long and 2 inches wide.  On 12-APR-2021, the patient experienced tiredness. On 13-APR-2021, the Patient experienced blisters on right arm between elbow and shoulder, shortness of breath, blurred vision an itching all over especially in right arm. On 13-APR-2021, the patient experienced fever of 101 F. Laboratory data included: Body temperature (NR: not provided) 101 F. On an unspecified date, the patient experienced scar on arm that was 4 inches long and 2 inches wide. The patient was hospitalized for 2 days. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from blisters on right arm between elbow and shoulder, shortness of breath, blurred vision, itching all over especially in right arm, tiredness, and fever of 101 F on 14-APR-2021, and the outcome of scar on arm that was 4 inches long and 2 inches wide was not reported. This report was serious (Hospitalization Caused / Prolonged).; Sender's Comments: V0: 20210435619-COVID-19 VACCINE AD26.COV2.S-blisters on right arm between elbow and shoulder, shortness of breath, blurred vision, itching all over especially in right arm. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s). 20210435619-COVID-19 VACCINE AD26.COV2.S-tiredness, fever of 101 F. This event(s) is labeled and is therefore considered potentially related.
Age: 46.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: International normalised ratio normal, Nikolsky's sign, Platelet count normal, Prothrombin time normal, Throat irritation
Clinical narrative: BLISTERS ON RIGHT ARM BETWEEN ELBOW AND SHOULDER; SHORTNESS OF BREATH; BLURRED VISION; ITCHING ALL OVER ESPECIALLY IN RIGHT ARM; FEVER OF 101 F; TIREDNESS; SCAR ON ARM THAT WAS 4 INCHES LONG AND 2 INCHES WIDE; This spontaneous report received from a patient concerned a 46 year old male. The patient's weight was 225 pounds, and height was 66 inches. The patient's past medical history included umbilical hernia, and covid-19, and concurrent conditions included high cholesterol, non-smoker, and social alcohol drinker, and other pre-existing medical conditions included the patient had no known allergies. The patient had no history of drug abuse or illicit drug use. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 206A21A, expiry: UNKNOWN) dose was not reported, administered on 12-APR-2021 for prophylactic vaccination. Concomitant medications included atorvastatin calcium for high cholesterol. On APR-2021, treatment medications included: diphenhydramine hydrochloride, oxygen, and paracetamol. Also given unspecified cream for right arm. He wanted help with the scar on arm that was 4 inches long and 2 inches wide.  On 12-APR-2021, the patient experienced tiredness. On 13-APR-2021, the Patient experienced blisters on right arm between elbow and shoulder, shortness of breath, blurred vision an itching all over especially in right arm. On 13-APR-2021, the patient experienced fever of 101 F. Laboratory data included: Body temperature (NR: not provided) 101 F. On an unspecified date, the patient experienced scar on arm that was 4 inches long and 2 inches wide. The patient was hospitalized for 2 days. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from blisters on right arm between elbow and shoulder, shortness of breath, blurred vision, itching all over especially in right arm, tiredness, and fever of 101 F on 14-APR-2021, and the outcome of scar on arm that was 4 inches long and 2 inches wide was not reported. This report was serious (Hospitalization Caused / Prolonged).; Sender's Comments: V0: 20210435619-COVID-19 VACCINE AD26.COV2.S-blisters on right arm between elbow and shoulder, shortness of breath, blurred vision, itching all over especially in right arm. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s). 20210435619-COVID-19 VACCINE AD26.COV2.S-tiredness, fever of 101 F. This event(s) is labeled and is therefore considered potentially related.
Age: 46.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Vaccination site erythema, Vaccination site pain, Vaccination site reaction
Clinical narrative: BLISTERS ON RIGHT ARM BETWEEN ELBOW AND SHOULDER; SHORTNESS OF BREATH; BLURRED VISION; ITCHING ALL OVER ESPECIALLY IN RIGHT ARM; FEVER OF 101 F; TIREDNESS; SCAR ON ARM THAT WAS 4 INCHES LONG AND 2 INCHES WIDE; This spontaneous report received from a patient concerned a 46 year old male. The patient's weight was 225 pounds, and height was 66 inches. The patient's past medical history included umbilical hernia, and covid-19, and concurrent conditions included high cholesterol, non-smoker, and social alcohol drinker, and other pre-existing medical conditions included the patient had no known allergies. The patient had no history of drug abuse or illicit drug use. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 206A21A, expiry: UNKNOWN) dose was not reported, administered on 12-APR-2021 for prophylactic vaccination. Concomitant medications included atorvastatin calcium for high cholesterol. On APR-2021, treatment medications included: diphenhydramine hydrochloride, oxygen, and paracetamol. Also given unspecified cream for right arm. He wanted help with the scar on arm that was 4 inches long and 2 inches wide.  On 12-APR-2021, the patient experienced tiredness. On 13-APR-2021, the Patient experienced blisters on right arm between elbow and shoulder, shortness of breath, blurred vision an itching all over especially in right arm. On 13-APR-2021, the patient experienced fever of 101 F. Laboratory data included: Body temperature (NR: not provided) 101 F. On an unspecified date, the patient experienced scar on arm that was 4 inches long and 2 inches wide. The patient was hospitalized for 2 days. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from blisters on right arm between elbow and shoulder, shortness of breath, blurred vision, itching all over especially in right arm, tiredness, and fever of 101 F on 14-APR-2021, and the outcome of scar on arm that was 4 inches long and 2 inches wide was not reported. This report was serious (Hospitalization Caused / Prolonged).; Sender's Comments: V0: 20210435619-COVID-19 VACCINE AD26.COV2.S-blisters on right arm between elbow and shoulder, shortness of breath, blurred vision, itching all over especially in right arm. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s). 20210435619-COVID-19 VACCINE AD26.COV2.S-tiredness, fever of 101 F. This event(s) is labeled and is therefore considered potentially related.
Age: 46.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Body temperature, Dyspnoea, Fatigue, Injection site vesicles, Pruritus
Clinical narrative: BLISTERS ON RIGHT ARM BETWEEN ELBOW AND SHOULDER; SHORTNESS OF BREATH; BLURRED VISION; ITCHING ALL OVER ESPECIALLY IN RIGHT ARM; FEVER OF 101 F; TIREDNESS; SCAR ON ARM THAT WAS 4 INCHES LONG AND 2 INCHES WIDE; This spontaneous report received from a patient concerned a 46 year old male. The patient's weight was 225 pounds, and height was 66 inches. The patient's past medical history included umbilical hernia, and covid-19, and concurrent conditions included high cholesterol, non-smoker, and social alcohol drinker, and other pre-existing medical conditions included the patient had no known allergies. The patient had no history of drug abuse or illicit drug use. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 206A21A, expiry: UNKNOWN) dose was not reported, administered on 12-APR-2021 for prophylactic vaccination. Concomitant medications included atorvastatin calcium for high cholesterol. On APR-2021, treatment medications included: diphenhydramine hydrochloride, oxygen, and paracetamol. Also given unspecified cream for right arm. He wanted help with the scar on arm that was 4 inches long and 2 inches wide.  On 12-APR-2021, the patient experienced tiredness. On 13-APR-2021, the Patient experienced blisters on right arm between elbow and shoulder, shortness of breath, blurred vision an itching all over especially in right arm. On 13-APR-2021, the patient experienced fever of 101 F. Laboratory data included: Body temperature (NR: not provided) 101 F. On an unspecified date, the patient experienced scar on arm that was 4 inches long and 2 inches wide. The patient was hospitalized for 2 days. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from blisters on right arm between elbow and shoulder, shortness of breath, blurred vision, itching all over especially in right arm, tiredness, and fever of 101 F on 14-APR-2021, and the outcome of scar on arm that was 4 inches long and 2 inches wide was not reported. This report was serious (Hospitalization Caused / Prolonged).; Sender's Comments: V0: 20210435619-COVID-19 VACCINE AD26.COV2.S-blisters on right arm between elbow and shoulder, shortness of breath, blurred vision, itching all over especially in right arm. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s). 20210435619-COVID-19 VACCINE AD26.COV2.S-tiredness, fever of 101 F. This event(s) is labeled and is therefore considered potentially related.
Age: 46.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pyrexia, Scar, Vision blurred
Clinical narrative: BLISTERS ON RIGHT ARM BETWEEN ELBOW AND SHOULDER; SHORTNESS OF BREATH; BLURRED VISION; ITCHING ALL OVER ESPECIALLY IN RIGHT ARM; FEVER OF 101 F; TIREDNESS; SCAR ON ARM THAT WAS 4 INCHES LONG AND 2 INCHES WIDE; This spontaneous report received from a patient concerned a 46 year old male. The patient's weight was 225 pounds, and height was 66 inches. The patient's past medical history included umbilical hernia, and covid-19, and concurrent conditions included high cholesterol, non-smoker, and social alcohol drinker, and other pre-existing medical conditions included the patient had no known allergies. The patient had no history of drug abuse or illicit drug use. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 206A21A, expiry: UNKNOWN) dose was not reported, administered on 12-APR-2021 for prophylactic vaccination. Concomitant medications included atorvastatin calcium for high cholesterol. On APR-2021, treatment medications included: diphenhydramine hydrochloride, oxygen, and paracetamol. Also given unspecified cream for right arm. He wanted help with the scar on arm that was 4 inches long and 2 inches wide.  On 12-APR-2021, the patient experienced tiredness. On 13-APR-2021, the Patient experienced blisters on right arm between elbow and shoulder, shortness of breath, blurred vision an itching all over especially in right arm. On 13-APR-2021, the patient experienced fever of 101 F. Laboratory data included: Body temperature (NR: not provided) 101 F. On an unspecified date, the patient experienced scar on arm that was 4 inches long and 2 inches wide. The patient was hospitalized for 2 days. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from blisters on right arm between elbow and shoulder, shortness of breath, blurred vision, itching all over especially in right arm, tiredness, and fever of 101 F on 14-APR-2021, and the outcome of scar on arm that was 4 inches long and 2 inches wide was not reported. This report was serious (Hospitalization Caused / Prolonged).; Sender's Comments: V0: 20210435619-COVID-19 VACCINE AD26.COV2.S-blisters on right arm between elbow and shoulder, shortness of breath, blurred vision, itching all over especially in right arm. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s). 20210435619-COVID-19 VACCINE AD26.COV2.S-tiredness, fever of 101 F. This event(s) is labeled and is therefore considered potentially related.
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Deep vein thrombosis, Nausea, Ultrasound Doppler abnormal, Vomiting
Clinical narrative: headaches, abdominal pain, leg swelling, very lethargy, Nausea & vomiting wheezing and fever
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain, Blood test, Headache, Lethargy, Nausea
Clinical narrative: headaches, abdominal pain, leg swelling, very lethargy, Nausea & vomiting wheezing and fever
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Peripheral swelling, Pyrexia, Thrombosis, Vomiting, Wheezing
Clinical narrative: headaches, abdominal pain, leg swelling, very lethargy, Nausea & vomiting wheezing and fever
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abortion spontaneous, Anticoagulant therapy, Exposure during pregnancy, Pelvic venous thrombosis, Ultrasound antenatal screen abnormal
Clinical narrative: BLOOD CLOT IN PELVIC VEIN; ABDOMINAL PAIN; NAUSEA; VOMITING; CHILLS; BODYACHE; DRUG EXPOSURE DURING PREGNANCY; MISCARRIAGE; This spontaneous pregnancy self-report concerned a 25 year old female patient. The patient's weight, height, and medical history were not reported. It was not reported whether the patient had been pregnant before. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: 1808978) dose was not reported, administered on 01-APR-2021 to right deltoid for prophylactic vaccination. No concomitant medications were reported.  On 01-APR-2021, the patient received the vaccine and experienced drug exposure during pregnancy. The date of the patient's last menstrual period and expected delivery date were not reported. On 02-APR-2021, within 24 hours of receiving the vaccine, the patient experienced abdominal pain, nausea, vomiting, chills, body ache. On 10-APR-2021, the patient experienced blood clot in pelvic vein. On an unspecified date in APR-2021, 2 weeks after receiving the vaccine, the patient experienced miscarriage as confirmed by her OBGYN.   Treatment included iron infusion, Pradaxa (dabigatran etexilate mesilate) and also getting blood work twice a week.  The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from vomiting on 08-APR-2021, and had not recovered from blood clot in pelvic vein, miscarriage, drug exposure during pregnancy, abdominal pain, nausea, chills, and body ache. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: This report on a 25 year old , female patient who suffered a miscarriage around 2 weeks (specific date not specified) after receiving the covid-19 vaccine ad26.cov.2 at the right deltoid. The patient's height and weight were not reported. No other medical history and concomitant medications reported. No allergies reported.  One (1) day after receiving the vaccine, the patient experienced abdominal pain, nausea, vomiting, chills and body ache. Ten (10) days after receiving the vaccine, patient was noted to have blood clot in the pelvic vein, actual result not reported. The information provided precludes a meaningful medical assessment. Additional information requested.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain, Abortion spontaneous, Blood test, Chills, Exposure during pregnancy
Clinical narrative: BLOOD CLOT IN PELVIC VEIN; ABDOMINAL PAIN; NAUSEA; VOMITING; CHILLS; BODYACHE; DRUG EXPOSURE DURING PREGNANCY; MISCARRIAGE; This spontaneous pregnancy self-report concerned a 25 year old female patient. The patient's weight, height, and medical history were not reported. It was not reported whether the patient had been pregnant before. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: 1808978) dose was not reported, administered on 01-APR-2021 to right deltoid for prophylactic vaccination. No concomitant medications were reported.  On 01-APR-2021, the patient received the vaccine and experienced drug exposure during pregnancy. The date of the patient's last menstrual period and expected delivery date were not reported. On 02-APR-2021, within 24 hours of receiving the vaccine, the patient experienced abdominal pain, nausea, vomiting, chills, body ache. On 10-APR-2021, the patient experienced blood clot in pelvic vein. On an unspecified date in APR-2021, 2 weeks after receiving the vaccine, the patient experienced miscarriage as confirmed by her OBGYN.   Treatment included iron infusion, Pradaxa (dabigatran etexilate mesilate) and also getting blood work twice a week.  The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from vomiting on 08-APR-2021, and had not recovered from blood clot in pelvic vein, miscarriage, drug exposure during pregnancy, abdominal pain, nausea, chills, and body ache. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: This report on a 25 year old , female patient who suffered a miscarriage around 2 weeks (specific date not specified) after receiving the covid-19 vaccine ad26.cov.2 at the right deltoid. The patient's height and weight were not reported. No other medical history and concomitant medications reported. No allergies reported.  One (1) day after receiving the vaccine, the patient experienced abdominal pain, nausea, vomiting, chills and body ache. Ten (10) days after receiving the vaccine, patient was noted to have blood clot in the pelvic vein, actual result not reported. The information provided precludes a meaningful medical assessment. Additional information requested.